Aeterna Zentaris Inc
F:ET8
Aeterna Zentaris Inc
Research & Development
Aeterna Zentaris Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aeterna Zentaris Inc
F:ET8
|
Research & Development
-$5.3m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
12%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Research & Development
-CA$11.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$29.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$272.7m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-34%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Research & Development
-CA$14.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Research & Development
-$94.5m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Aeterna Zentaris Inc
Glance View
Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.
See Also
What is Aeterna Zentaris Inc's Research & Development?
Research & Development
-5.3m
USD
Based on the financial report for Sep 30, 2025, Aeterna Zentaris Inc's Research & Development amounts to -5.3m USD.
What is Aeterna Zentaris Inc's Research & Development growth rate?
Research & Development CAGR 10Y
12%
Over the last year, the Research & Development growth was 43%. The average annual Research & Development growth rates for Aeterna Zentaris Inc have been 26% over the past three years , -36% over the past five years , and 12% over the past ten years .
